Impact Factor
4.33
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
6.77
1,538 total citations
h5-index
61
h5 depth signal
Cited share
91.1%
226 of 248
Total citations
1,538
Citation footprint
Metric signal
7.45
External metric anchor
Self-citation
1.2%
19 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
United States
731
China
430
France
360
Germany
314
Italy
161
Citing Fields of Research
Immunology
2,140
Immunotherapy
560
Oncology
510
Breast Cancer
156
Cancer, Autophagy & Apoptosis
136
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
3,872
Articles tracked across the journal lifetime
Indexed publication set
248
226 cited publications
Last 12 months
106
8.8 publications/month
Open access share
100.0%
106 OA publications in the last year
Leading citing country
United States
731 citing publications
Leading citing field
Immunology
2,140 citing publications
Latest tracked publication
18 October 2026
10 recent records available
Coverage & Indexing History
v9n1, 2020-
v3n1, 2014- ; Selected citations only before this date
Active Coverage
Research Focus & Classification
Indexed Subjects
Immunology
Broad Categories
Allergy and Immunology
Neoplasms
Immunology
MeSH Descriptors
Immunotherapy
Neoplasms
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
DOI 10.1080/2162402x.2026.2745295
Open DOI
Glioblastoma immune landscape remodeling following treatment with CD70-targeted CAR-T cells
02
DOI 10.1080/2162402x.2026.2748140
Open DOI
Biomarkers of subclinical cholestasis predict cancer immunotherapy outcomes
03
DOI 10.1080/2162402x.2026.2740432
Open DOI
Targeting tumor-selective membrane-associated PCNA enables selective antibody–drug conjugate therapy
04
DOI 10.1080/2162402x.2026.2746847
Open DOI
Estradiol-associated extracellular signaling in the human breast in vivo identifies mast cells as tumor-supportive stromal mediators
05
DOI 10.1080/2162402x.2026.2740845
Open DOI
A novel oncolytic peptide synergizing with immunotherapy
06
07
DOI 10.1080/2162402x.2026.2738262
Open DOI
Circadian timing of first-line chemoimmunotherapy is associated with survival in extensive-stage small cell lung cancer
1. Despite the addition of immune checkpoint inhibitors (ICIs) to platinum-etoposide as first-line therapy, extensive-stage small cell lung cancer (ES-SCLC) remains a highly lethal disease, with a ...
08
DOI 10.1080/2162402x.2026.2736339
Open DOI
Modular mRNA cocktail enables synergistic activation of antigen-specific T cells for cancer immunotherapy
MRNA-based therapeutics have dramatically accelerated the development of vaccines for infectious disease. This accelerated timeline is evident in the significant progress achieved in less than a ye...
09
DOI 10.1080/2162402x.2026.2736333
Open DOI
IL-15 trans-presentation at the innate-adaptive interface: mechanisms and translation in cancer immunotherapy
Durable antitumor immunity requires coordinated completion of the cancer-immunity cycle: tumor-antigen release, dendritic-cell capture and cross-presentation, T-cell priming, effector trafficking, ...
10
DOI 10.1080/2162402x.2026.2706271
Open DOI
X‑ray FLASH RT inhibits lung cancer bone metastasis via activating CD4⁺ T-cell‑mediated antitumor immunity with modulation of Th17 cell response
Lung cancer is a group of malignant tumors characterized by rapid progression and poor prognosis and is the leading cause of cancer deaths worldwide. 1 Distant metastasis is the leading cause of de...
Bibliographical & Catalog Notes
Print issues ceased with v.1 (2012)
Also issued online.